Post-earnings recap
Reported
Thu, Jul 23, 2026
EPS actual
$6.03
EPS est.
$5.71
EPS surprise
+5.59%
1-day move
+8.71%
Thermo Fisher Scientific's earnings report showed a positive surprise in EPS, which likely contributed to the stock's significant increase of 8.71%. The lack of revenue data means investors will need to wait for further details to fully assess the company's performance. Overall, the strong EPS figure suggests that the company is managing its costs effectively or benefiting from higher margins.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $6.03 | N/A | +5.59% |
| Revenue | N/A | N/A | N/A |
No transcript is on record for the earnings call, so analysis is based solely on numerical results.
Thermo Fisher Scientific Inc. (TMO) is a leading company in the health care sector, specializing in life sciences tools and services. Their products and services are critical for research, diagnostics, and laboratory workflows, making them an essential player in the ongoing advancements in health care and biotechnology.
Last quarter
In Q1-2026, Thermo Fisher reported an EPS of $5.44, beating estimates by 4.68%. Despite the positive earnings surprise, the stock dropped 9.20% the next day, indicating potential market concerns.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+3.14%
Avg 1-day reaction
+1.51%
Investors are cautiously optimistic about Thermo Fisher's upcoming earnings, given their strong track record of beating EPS estimates. However, the recent stock price drop raises questions about market sentiment and future guidance.
Bull case
If Thermo Fisher continues its trend of beating EPS estimates and shows strong revenue growth, it could lead to a positive market reaction and renewed investor confidence.
Bear case
Conversely, if the company fails to meet expectations or provides weak guidance, it could exacerbate recent stock declines and lead to further investor skepticism.
The print will turn on these.
Q1
What will the EPS be for Q2-2026?
Given the company's history of beating EPS estimates, this figure will be crucial for investor confidence and market reaction.
Q2
How does management plan to address recent stock performance?
Investors will be looking for reassurance on future growth strategies and operational improvements to mitigate recent declines.
—
Est. EPS
$4.19
Est. Rev
$1.2B
Impl. Move
±16.2%
Why consensus could be wrong
The Street may be underestimating Thermo Fisher's ability to leverage its recent product innovations, which could drive stronger-than-expected revenue growth this quarter.
Supporting evidence
The company has consistently beaten EPS estimates, indicating strong operational performance.
Recent investments in R&D may yield new products that could boost sales significantly.
Options pricing suggests a much larger move than historical averages, indicating potential for a surprise.
Key risk
If revenue growth exceeds expectations due to new product launches, it could challenge the current cautious consensus.
Pre-commit to what would confirm each case.
The core debate this quarter revolves around whether Thermo Fisher can maintain its earnings momentum amid market challenges.
Bull confirmed if
An EPS of $5.60 or higher would confirm the bull case and likely lead to a positive market reaction.
Bear confirmed if
An EPS below $5.20 would validate the bear case and could lead to further declines in stock price.
What the market is pricing for the move.
Implied Move
±14.5%
Historical Avg
±4.5%
The options market is pricing in a significant potential move following the earnings report, suggesting that investors expect volatility.
Options are pricing a 14.5% move, while the stock has averaged only 4.5% over the last 8 quarters — setup is rich.
ATM IV
0.3%
30d HV
41.3%
Smart-money positioning from the most recent 13F filings.
Institutional
94.08%
of float
Insider
0.13%
of float
Holders
3,552
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
30,919,632 sh · $20.5B
8.36%
1.6%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Thermo Fisher beats expectations, history suggests the stock could rise by about 0.93% on the following day, confirming a positive outlook.
In line / cautious
If results are in line with expectations, the stock may experience muted movement as investors assess management's commentary.
Miss
A miss could lead to a decline in stock price, with historical patterns suggesting a potential drop of around 4.48%.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
2
0 buys·2 sells
Members
2
House only
Est. Notional
$2,002.00–$30,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Vanguard Capital Management LLC
24,276,316 sh · $16.1B
6.57%
-0.0%
State Street Corporation
16,825,879 sh · $11.1B
4.55%
0.6%
FMR, LLC
14,084,488 sh · $9.3B
3.81%
30.7%
Morgan Stanley
10,763,066 sh · $7.1B
2.91%
-0.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net selling
1 trade
Net selling
Recent Transactions
Traded Jul 10, 2026 · disclosed Jul 17, 2026
$1,001.00–$15,000.00
Traded May 7, 2026 · disclosed May 15, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.